Status:
RECRUITING
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions:
Leukemia, Lymphoblastic
Eligibility:
All Genders
18+ years
Brief Summary
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the co...
Detailed Description
Survival rates from Acute lymphoblastic leukemia (ALL) have improved dramatically over the past four decades but vary significantly with age. Children treated on modern protocols have survival rates e...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study;
- Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL;
- Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;
- Participant is willing and able to give informed consent for participation in the study;
- Male or Female, aged \>18 years;
- Availability of clinical data.
Exclusion
- Age \< 18 years;
- B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.
- Low blast percentage (\<70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;
Key Trial Info
Start Date :
October 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06919393
Start Date
October 23 2019
End Date
January 1 2026
Last Update
April 9 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Irst Irccs
Meldola, FC, Italy, 47014
2
Ospedale S. Maria delle Croci RAVENNA
Ravenna, RA, Italy, 48121
3
Ospedale Infermi
Rimini, RN, Italy, 47923